[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Gomyo H, Kagami Y, Kato H, Kawase T, Ohshiro A, Oyama T, Kamiya Y, Taji H, Nakamura S, Ogura M, Morishima Y: Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes. J Clin Exp Hematop; 2007 Nov;47(2):73-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes.
  • This report concerns a rare case of follicular lymphoma with features suggestive of primary hepatic lymphoma.
  • At the disease onset, multiple nodular lesions in the liver and small para-aortic nodes were detected by abdominal magnetic resonance imaging without generalized lymphadenopathy.
  • To the best of our knowledge, this is the ninth report of primary hepatic follicular lymphoma.
  • Insufficient cases have been reported to determine the long-term outcome and clinical characteristics of primary hepatic follicular lymphoma.
  • However, it seems that patients with primary hepatic follicular lymphoma that are treated with appropriate chemotherapy with or without surgical resection have favorable outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040146.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM: Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol; 2006 Dec;81(12):969-72
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.
  • Hepatitis B reactivation is a well-known complication during or after chemotherapy in chronic hepatitis B (HBV) carriers.
  • The current practice guidelines in Canada and the United States recommends patients receive antiviral prophylaxis prior to the onset of chemotherapy in chronic HBV carriers with lamivudine.
  • We report a case of a 57-year-old man with follicular lymphoma on lamivudine prophylaxis and no clinical evidence of cirrhosis, and developed fatal HBV reactivation after the emergence of a YMDD mutant strain of HBV that confers lamivudine resistance.
  • Our experience indicates the need to carefully monitor patients for suspected drug- resistant HBV mutants with the addition of anti-viral agents effective against the YMDD mutational strain, when lamivudine resistance emerges.
  • [MeSH-major] Drug Resistance, Viral. Hepatitis B, Chronic / prevention & control. Lamivudine / administration & dosage. Reverse Transcriptase Inhibitors / administration & dosage. Virus Activation / drug effects
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fatal Outcome. Humans. Liver Cirrhosis / etiology. Liver Cirrhosis / genetics. Lymphoma, Follicular / complications. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / virology. Male. Middle Aged. Mutation

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937392.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


3. Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A: Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. Clin Cancer Res; 2002 Apr;8(4):1277-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
  • The t(14;18) is present in 85-90% of follicular lymphomas.
  • Bcl-2 antisense oligonucleotides (ODNs) down-regulate Bcl-2 expression and inhibit growth of the follicular lymphoma cell line WSU-FSCCL.
  • In this study, we have established a human lymphoma xenograft model in severe combined immunodeficient (SCID) mice using the WSU-FSCCL cell line. s.c., i.v., or i.p. injection of WSU-FSCCL cells into SCID mice results in the development of disseminated tumors, with the liver, spleen, bone marrow, and lymph nodes as major sites of disease.
  • Phosphorothioate ODNs against the translation initiation site of bcl-2 mRNA in the antisense and mismatched antisense sequences were administered i.v. or i.p. to the xenograft models three times a week for 2 weeks, starting on day 7 after tumor injections.
  • More significantly, a pathological examination showed no tumor in the liver, spleen, or bone marrow of the antisense group.
  • We conclude that bcl-2 antisense ODN therapy is effective against systemic FSCCL disease in SCID mice xenografts; however, it does not prevent disease dissemination into the central nervous system causing animal death.
  • [MeSH-major] DNA, Antisense / pharmacology. Lymphoma, Follicular / drug therapy. Nervous System Diseases / drug therapy. Proto-Oncogene Proteins c-bcl-2 / genetics
  • [MeSH-minor] Animals. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Female. Flow Cytometry. Humans. Immunophenotyping. Karyotyping. Mice. Mice, SCID. Neoplasm Transplantation. Oligonucleotides / pharmacology. Translocation, Genetic. Treatment Outcome. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11948143.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 22453-20
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Antisense; 0 / Oligonucleotides; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


Advertisement
4. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science; 2008 Aug 15;321(5891):974-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of target cells in blood.
  • Blinatumomab also led to clearance of tumor cells from bone marrow and liver.
  • T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
  • [MeSH-major] Antibodies, Bispecific / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] B-Lymphocytes / immunology. Humans. Immunologic Memory. Immunophenotyping. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphocyte Count. Recurrence. T-Lymphocytes / immunology


5. Li X, Lin Q, Dong M, Wen JY, Wei L, Ma XK, Chen ZH, Wu XY: Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma; 2010 Sep;51(9):1678-85
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
  • The prognosis and management of acute exacerbations of hepatitis-B in patients with lymphoma after chemotherapy in combination with rituximab remain unclear.
  • Here, we describe 19 Chinese patients with lymphoma who suffered this complication, in order to analyze their clinical characteristics.
  • We found that key prognostic factors included the peak prothrombin time (PT), international normalized ratio (INR), and total bilirubin (TB), as well as the PT and INR on admission and the interval between acute exacerbation of hepatitis-B and the last cycle of chemotherapy.
  • Our results revealed that the severity of hepatic damage and the interval between the last cycle of chemotherapy and hepatitis flare were the major prognostic factors of an acute exacerbation of hepatitis-B induced by immunochemotherapy.
  • Prophylactic antiviral and rescue antiviral therapy remain to be further characterized.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hepatitis B / etiology. Hepatitis B virus / physiology. Lymphoma, B-Cell, Marginal Zone / virology. Lymphoma, Follicular / virology. Lymphoma, Large B-Cell, Diffuse / virology. Virus Activation / drug effects
  • [MeSH-minor] Acute Disease. Adult. Aged. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antibodies, Monoclonal, Murine-Derived / adverse effects. Antiviral Agents / therapeutic use. Bilirubin / metabolism. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. DNA, Viral / genetics. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Liver Function Tests. Male. Middle Aged. Polymerase Chain Reaction. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Prothrombin Time. Rituximab. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Sep;51(9):1592-5 [20807092.001]
  • (PMID = 20807095.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antiviral Agents; 0 / DNA, Viral; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RFM9X3LJ49 / Bilirubin; VB0R961HZT / Prednisone
  •  go-up   go-down


6. Cannizzo E, Sohani AR, Ferry JA, Hochberg EP, Kluk MJ, Dorn ME, Sadowski C, Bucci JJ, Ackerman AM, Longtine JA, Carulli G, Preffer FI: Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors. J Hematop; 2009;2(3):163-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old man with adenopathy was admitted to the hospital, and lymph node biopsy was positive for low-grade follicular lymphoma.
  • He achieved a partial remission with chemotherapy.
  • Simultaneously, he was diagnosed with diffuse large B cell lymphoma in a neck lymph node; after chemo- and radiotherapy, he achieved a complete response.
  • A restaging PET-CT scan 2 years later revealed a retroperitoneal nodule, and biopsy again showed a low-grade follicular lymphoma, while a biopsy of a cutaneous scalp lesion showed a CD30-positive peripheral T cell lymphoma.
  • After some months, a liver biopsy and a right cervical lymph node biopsy showed a CD30-positive peripheral T cell lymphoma consistent with anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
  • Flow cytometry and cytogenetic and molecular genetic analysis performed at diagnosis and during the patient's follow-up confirmed the presence of two clonally distinct B cell lymphomas, while the two T cell neoplasms were confirmed to be clonally related.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 2):1079-82 [12423812.001]
  • [Cites] J Chemother. 2003 Aug;15(4):406-8 [12962371.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1489-97 [17372278.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):630-6 [11979093.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):239-42 [9700587.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):161-8 [10194134.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):123-7 [10966173.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):997-1005 [11592772.001]
  • [Cites] Rinsho Ketsueki. 1986 Dec;27(12):2313-8 [3573322.001]
  • (PMID = 20309424.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2766444
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Cytogenetics / Diffuse large B cell lymphoma / Follicular lymphoma / Multiple malignancies / Risk factors
  •  go-up   go-down


7. Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, Silverman DH, Witzig TE, Sparks RB, White CA: Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer; 2002 Feb 15;94(4 Suppl):1349-57
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
  • Previous trials involving rituximab-naïve patients have demonstrated excellent targeting of Zevalin to CD20+ B-cell non-Hodgkin lymphoma with minimal uptake in normal organs.
  • METHODS: Twenty-seven patients were given an imaging dose of 5 mCi (185 MBq) (111)In-Zevalin on Day 0, evaluated with dosimetry, and then given a therapeutic dose of 0.4 mCi/kg (15 MBq/kg) (90)Y-Zevalin on Day 7.
  • Residence times for (90)Y in blood and major organs were estimated from (111)In biodistribution, and the MIRDOSE3 computer software program was used to calculate absorbed radiation doses to organs and red marrow.
  • RESULTS: Median estimated absorbed radiation doses from (90)Y-Zevalin were 8.1 Gray (Gy) (range, 4.2-23.0 Gy) to the spleen, 5.1 Gy (range, 2.6-12.0 Gy) to the liver, 2.0 Gy (range, 1.4-5.3 Gy) to the lungs, 0.22 Gy (range, < 0.01-0.66 Gy) to the kidneys, and 0.74 Gy (range, 0.29-1.2 Gy) to the red marrow.
  • CONCLUSIONS: Zevalin treatment of rituximab-refractory follicular NHL patients at 0.4 mCi/kg resulted in acceptable estimates of absorbed radiation dose to organs, similar to those observed in other Zevalin-treated populations.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Drug Resistance, Neoplasm. Humans. Radioimmunotherapy. Radiometry. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11877765.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


8. Yousuf MY, Imran F, Davis A: A rare association of B cell lymphoma and ectodermal dysplasia presenting with protein-losing enteropathy. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare association of B cell lymphoma and ectodermal dysplasia presenting with protein-losing enteropathy.
  • Investigations ruled out protein loss from the kidney and there was no evidence of chronic liver disease.
  • Protein-losing enteropathy became a diagnosis of exclusion.
  • To investigate it further, he underwent an oral gastroduodenoscopy and a computed tomography scan of the abdomen, which showed an abnormal duodenal mucosa and extensive retroperitoneal lymphadenopathy.
  • Biopsies confirmed this to be grade II follicular non-Hodgkin lymphoma.
  • He received a course of steroids and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Aug 18;24(35):5521-4 [16007185.001]
  • [Cites] Cell. 1999 Oct 15;99(2):143-53 [10535733.001]
  • [Cites] S Afr Med J. 1980 Jun 14;57(24):1009-11 [7404069.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Aug;90(2):124-5 [10936828.001]
  • [Cites] South Med J. 1975 Mar;68(3):354-7 [1173007.001]
  • [Cites] Trends Mol Med. 2002 Mar;8(3):133-9 [11879774.001]
  • [Cites] Am J Med Genet. 2002 Oct 15;112(3):284-90 [12357472.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):363-73 [15837625.001]
  • [Cites] J Pathol. 2005 Jul;206(3):337-45 [15887287.001]
  • [Cites] Postgrad Med J. 1988 Apr;64(750):313-4 [3186577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8435-40 [16714381.001]
  • [Cites] Jpn J Clin Oncol. 1996 Aug;26(4):264-72 [8765187.001]
  • [Cites] Intern Med. 1997 Aug;36(8):556-60 [9260772.001]
  • [Cites] Z Gastroenterol. 1995 Apr;33(4):209-13 [7793120.001]
  • [Cites] J Dent Res. 2003 Jun;82(6):433-7 [12766194.001]
  • [Cites] Am J Med Genet A. 2003 Jul 30;120A(3):370-3 [12838557.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):240-7 [15551738.001]
  • [Cites] Rinsho Ketsueki. 1989 Dec;30(12):2210-4 [2621805.001]
  • [Cites] Postgrad Med J. 1986 May;62(727):399-400 [3763551.001]
  • (PMID = 21686749.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028173
  •  go-up   go-down


9. Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ: Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant; 2000;6(5A):555-62
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
  • We conducted a pilot study in 20 patients with high-risk or recurrent/refractory non-Hodgkin's lymphoma (NHL) using high-dose sequential chemotherapy (HDSC) and autologous hematopoietic cell transplantation (AHCT).
  • After cytoreduction with standard salvage therapy, HDSC/AHCT was administered in 4 phases at 2- to 4-week intervals.
  • The NHL histologies were diffuse large cell, follicular/diffuse mixed, small noncleaved cell, T-cell-rich B-cell, lymphoblastic, and peripheral T cell.
  • Treatment-related toxicities in the remaining 11 transplant recipients were cardiomyopathy, hemorrhagic cystitis, persistent cytopenias, acute renal failure, abnormal liver function test results, and infectious complications.
  • There were no treatment-related deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Purging. Hematopoietic Stem Cell Mobilization / adverse effects. Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Adult. Bone Marrow Diseases / chemically induced. Cardiomyopathies / chemically induced. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cystitis / chemically induced. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Drug-Induced Liver Injury / etiology. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Hemorrhage / chemically induced. Humans. Infection. Leucovorin / administration & dosage. Life Tables. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Pilot Projects. Salvage Therapy. Survival Analysis. Survival Rate. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11071261.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Christophides T, Samstein B, Emond J, Bhagat G: Primary follicular lymphoma of the extrahepatic bile duct mimicking a hilar cholangiocarcinoma: case report and review of the literature. Hum Pathol; 2009 Dec;40(12):1808-12
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the extrahepatic bile duct mimicking a hilar cholangiocarcinoma: case report and review of the literature.
  • We report a case of a 53-year-old Asian woman who presented with abdominal pain, bloating, dysphagia, and signs of incomplete biliary obstruction, having elevated liver function tests but without increased bilirubin.
  • Imaging studies revealed a mass measuring 6.0 x 8.0 cm at the porta hepatis extending to the right lobe of the liver and obstructing the common hepatic duct, causing mild to moderate intrahepatic biliary dilation and variable occlusion of the right portal vein.
  • At laparotomy, an infiltrative neoplasm was noted at the hilum that involved the common bile duct, right and left hepatic ducts, and the right lobe of the liver.
  • Histologic examination revealed a high grade follicular lymphoma (grade 3A) with a predominantly follicular pattern of growth.
  • Portal lymph nodes and a staging bone marrow biopsy showed no evidence of lymphoma.
  • The patient subsequently received chemotherapy.
  • To the best of our knowledge, this is the third report of a primary extranodal follicular lymphoma of the extrahepatic biliary system.
  • [MeSH-major] Bile Ducts, Extrahepatic / pathology. Lymphoma, Follicular / pathology
  • [MeSH-minor] Bile Duct Neoplasms / pathology. Cholangiocarcinoma / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Klatskin Tumor / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716158.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V, Zupo S, Marino G, Rubagotti A, Polacco A, Spriano M, Vimercati R, Congiu AM, Ravetti JL, Aversa S, Candela M, Patti C: Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group. Leuk Lymphoma; 2004 Jun;45(6):1141-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
  • The aim of the study was to determine the safety and efficacy of the combination of fludarabine (FLU), cyclophosphamide (CY) and mitoxantrone (FLU/CY/MITO) in untreated follicular lymphomas (FL), Sixty patients with newly diagnosed stage II bulky to IV FL, median age 59 years (range 36-70), received FLU/CY/MITO regimen (FLU 25 mg/m2 days 1-3, CY 300 mg/m2 days 1-3, Mito 10 mg/m2 day 1).
  • Patients received antibiotic oral prophylaxis during all treatments, and growth factors (G-CSF) when grade III granulocytopenia (WHO) occurred.
  • Fifty patients are surviving with a median observation time of 31 months.
  • Two patients suffered grade III pulmonary infection and one grade III liver toxicity.
  • At the end of treatment, 25 of these patients had CR and 19 (76%) converted to polymerase chain reaction (PCR) negativity.
  • FLU/CY/MITO regimen showed a high level of activity in follicular lymphoma.
  • Toxicity, mainly hematological, was acceptable and the treatment was made feasible by the use of antibiotic prophylaxis and G-CSF.
  • The conversion of bcl-2 from positive to negative by PCR in BM and/or PB suggests a possible role for this treatment in clearing minimal residual disease and improving patients' outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Bone Marrow. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm, Residual / drug therapy. Protein Transport. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Safety. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15359993.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


12. Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT: CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol; 2003 Sep;82(9):585-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
  • In 60% of low-grade B lymphomas in which rituximab was effective at first, there was no clinical response in a second treatment and a few cases of follicular lymphomas (FL) with transformation to diffuse large B-cell lymphoma (DLBCL) have been reported.
  • We describe a new case and hypothesize about the mechanisms of transformation: a 52-year-old man, in follow-up during 8 years for FL, who after rituximab treatment and complete remission of FL showed progressive disease involving the liver and duodenal mucosa.
  • Immunohistochemical and molecular studies were performed on paraffin-embedded tissue samples of lymph nodes, the small intestine, and liver tumors.
  • After rituximab treatment, biopsies of a liver lesion and the small bowel both showed CD20-negative large B-cell lymphoma.
  • The rapid relapse with the same rearrangement of IgH seems to support the interpretation that the change of grade of lymphoma and loss of CD20 expression occurred before rituximab treatment.
  • The existence of a varying proportion of a CD20-negative cell population in every B-cell lymphoma which does not respond to rituximab should therefore be considered.
  • The reduction of CD20 expression could be a resistance mechanism to rituximab retreatment in DLBCL as a consequence of the progression of low-grade B-cell non-Hodgkin's lymphoma (B-NHL).
  • It is necessary to perform new biopsies to evaluate CD20 expression in relapse or the progression of B-cell lymphoma after rituximab treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / analysis. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12898184.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


13. Cohen Y, Libster D, Da'as N, Amir G, Polliack A: Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab. Hematol J; 2003;4(2):151-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.
  • Two recent studies have shown that retreatment of patients with relapsed indolent NHL with rituximab (RI) can be as effective as primary treatment, provided the lymphoma was initially responsive to primary RI therapy.
  • Here, we describe a 47-year-old male with stage 4B follicular lymphoma (FL), initially also involving skin, who achieved complete remission (CR) after a combination of fludarabine, cyclophosphamide and RI that lasted only 5 months.
  • He soon relapsed with systemic disease and a number of extranodal sites including liver, lungs and bone marrow.
  • Another four infusions of RI were given 6 months later as maintenance therapy.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12750735.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


14. Azim HA, Elsedewy E, Azim HA Jr: Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature. Onkologie; 2007 Jul;30(7):381-4
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature.
  • Follicular dendritic cell sarcoma is a rare, malignant, non-lymphoid cell-derived tumor that originates from B-lymphoid follicles of nodal and extranodal sites.
  • Surgery and radiotherapy were considered the mainstay of treatment for localized disease.
  • As for the metastatic setting, classic lymphoma and sarcoma regimens were previously tested with dismal responses.
  • PATIENT AND METHODS: In this report, we examined imatinib in combination with gemcitabine and cisplatin for treating a male patient with metastatic follicular dendritic sarcoma to the liver and lung.
  • RESULTS: The patient achieved complete pathological remission confirmed by positron emission tomography (PET) scan after 8 cycles.
  • An imatinibbased combination could serve as a good therapeutic option for such cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells, Follicular. Head and Neck Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Sarcoma / secondary
  • [MeSH-minor] Benzamides. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Cisplatin / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Follow-Up Studies. Humans. Imatinib Mesylate. Lymphatic Metastasis / pathology. Male. Middle Aged. Positron-Emission Tomography. Proto-Oncogene Proteins c-kit / analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17596748.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 0W860991D6 / Deoxycytidine; 8A1O1M485B / Imatinib Mesylate; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 20
  •  go-up   go-down


15. Reiter A, Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Mann G, Schrappe M: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):10000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL).
  • : 10000 Background: Pediatric mature B-cell NHL differ from aggressive B-NHL of adults in terms of biology and treatment outcome.
  • In contrast to adults, rituximab (Rx) is not established in the treatment of pediatric B-NHL has not be determined yet.
  • Exclusion: Lansky performance scale 5, pre-treatment, impaired renal-, heart-, liver-function, hepatitis B, pre-existing disease, pregnancy.
  • TREATMENT: Rx 375 mg/m<sup>2</sup> IV at day 1; concomitant therapy: Rasburicase, steroids only for anaphylaxis, intrathecal (IT) triple drug at days 1, 3 for CNS+ pts only.
  • Begin of chemotherapy at day 5.
  • Forty-nine pts were not evaluable for response: Withdrawal (anaphylaxis 8, ATL 2, suspected progression, not verified 4, other 2), IT therapy in CNS- pts (8), corticosteroids (3), technical inadequacy of response evaluation (21), no index lesion (1).
  • RR by histology: BL/B-ALL 29/68, DLBCL 6/14, juvenile follicular lymphoma 1/2, PMBCL 1/1, B-NHL nfs 0/2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Xia ZJ, Wang FH, Huang HQ, Luo HY, Li YH, Lin TY, Jiang WQ, Guan ZZ: [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases]. Ai Zheng; 2006 Apr;25(4):490-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
  • BACKGROUND & OBJECTIVE: The efficacy of rituximab given alone or in combination with chemotherapy on naive or relapsed indolent lymphoma is good.
  • This study was to investigate the efficacy and safety of rituximab-containing regimens for patients with indolent B-cell lymphoma in China.
  • 2005, 34 patients with indolent B-cell lymphoma received rituximab-containing regimens with a median of 5 cycles (ranged from 3 to 8 cycles).
  • The overall response (OR) rate was 93.3%, and the complete response (CR) rate was 60.0%; the OR rate and CR rate of 22 evaluable naive patients were 95.4% and 66.7%, those of 18 evaluable follicular lymphoma patients were 88.9% and 66.7%.
  • Other adverse events included grade I-II nausea/vomiting, mild alopecia, and transient liver function abnormality.
  • CONCLUSION: Rituximab-containing chemotherapeutic regimens are effective for indolent B-cell lymphoma with mild toxicity.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukopenia / chemically induced. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Rituximab. Seizures, Febrile / chemically induced. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613687.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Suzumiya J, Suzushima H, Maeda K, Okamura S, Utsunomiya A, Shibuya T, Tamura K, Kyushu Hematology Organization for Treatment Study Group: Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol; 2004 Apr;79(3):266-70
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.
  • A phase I study of irinotecan hydrochloride (CPT-11), carboplatin, and dexamethasone treatment in 7 patients with relapsed lymphoma and 7 patients with refractory lymphoma was conducted to evaluate the maximal tolerated dose.
  • This study included patients with diffuse large B-cell lymphoma (n = 5), adult T-cell leukemia/lymphoma (n = 2), mantle cell lymphoma (n = 2), follicular lymphoma (n = 2), angioimmunoblastic T-cell lymphoma (n = 1), anaplastic large cell lymphoma (n = 1), and Hodgkin's lymphoma (n = 1).
  • All patients had received anthracycline-containing combination chemotherapy prior to this therapy.
  • Two patients who received 30 mg/m2 (level 4) of CPT-11 developed sepsis.
  • No deaths were related to this chemotherapy, and no patient developed liver dysfunction.
  • We conclude that the combination therapy of CPT-11, carboplatin, and dexamthasone is effective as salvage therapy but that the duration of response is too short.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Camptothecin / analogs & derivatives. Lymphoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1994 Oct;70(4):771-4 [7917938.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):594-600 [11857289.001]
  • [Cites] Gan To Kagaku Ryoho. 1988 Jul;15(7):2145-51 [3293537.001]
  • [Cites] Jpn J Clin Oncol. 1996 Dec;26(6):455-60 [9001351.001]
  • [Cites] Semin Oncol. 1996 Feb;23 (1 Suppl 3):21-6 [8633249.001]
  • [Cites] Gan To Kagaku Ryoho. 1991 Aug;18(10 ):1681-9 [1872624.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):115-6 [10690400.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1907-12 [2230878.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):604-10 [1537625.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):250-7 [8411739.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):411-6 [11529467.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1169-76 [8201379.001]
  • [Cites] Rinsho Ketsueki. 1994 Jul;35(7):635-41 [8065017.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):71-4 [3342468.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4187-91 [1651156.001]
  • [Cites] J Clin Oncol. 1992 Jan;10 (1):16-20 [1309380.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):909-13 [8487053.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jun;21(7):1047-55 [8210256.001]
  • [Cites] Blood. 1988 Jan;71(1):117-22 [3334893.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3633-42 [11054436.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):577-86 [11697485.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Aug;21(10 ):1607-11 [8060135.001]
  • (PMID = 15168596.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Sasaki S, Hatanaka K, Sahara N, Uekusa T, Hirayama K, Shirahata A, Ishimaru M: Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon: report of a case. Surg Today; 2010 Oct;40(10):975-81
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon: report of a case.
  • This report presents the case of a 62-year-old man with a collision tumor of primary malignant lymphoma and adenocarcinoma in the cecum.
  • All regional mesenteric lymph nodes that were removed surgically were found to be occupied by lymphoma cells and no lymph nodes contained any cancer cells, although the primary carcinomas did exhibit lymphatic invasion.
  • Malignant lymphoma was also seen in the duodenum.
  • Systemic chemotherapy was administered for the malignant lymphoma, and a complete response was thus obtained.
  • However, just after chemotherapy multiple liver metastases of adenocarcinoma emerged, and chemotherapy against adenocarcinoma was therefore continued.
  • The occurrence of synchronous lymphoma and adenocarcinoma of the colorectum is rare.
  • The accurate clinical determination of the dominant tumor and a close follow-up is required for proper treatment in these cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cecal Neoplasms / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy, Needle. Colectomy / methods. Colonoscopy. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):822-4 [6389052.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):188-92 [14530814.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Surg Today. 2008;38(7):647-50 [18612792.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E64-6 [12562254.001]
  • [Cites] Am J Epidemiol. 1976 Nov;104(5):517-22 [984025.001]
  • [Cites] Histopathology. 1988 Mar;12(3):235-52 [3366441.001]
  • [Cites] Postgrad Med J. 1995 Jul;71(837):443 [7567744.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):811-7 [11504842.001]
  • [Cites] Ann Surg. 1969 Aug;170(2):221-31 [5819579.001]
  • [Cites] Gastroenterology. 1947 Jun;8(6):695-710 [20251622.001]
  • [Cites] Am J Gastroenterol. 1983 Jun;78(6):341-5 [6859012.001]
  • [Cites] J R Coll Surg Edinb. 1983 Jan;28(1):58-60 [6834316.001]
  • [Cites] J Clin Pathol. 1960 Nov;13(6):483-9 [16810961.001]
  • [Cites] Am J Dig Dis. 1972 Mar;17(3):219-32 [4554148.001]
  • [Cites] Clin Oncol. 1979 Mar;5(1):85-9 [421390.001]
  • [Cites] Gan No Rinsho. 1985 Jun;31(7):894-9 [3928946.001]
  • [Cites] Gastroenterol Clin Biol. 1990;14(2):185-6 [2328885.001]
  • [Cites] Surg Clin North Am. 1959 Jun;39(3):725-35 [13659385.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):28-9 [9167378.001]
  • (PMID = 20872204.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Gockel HR, Heidemann J, Lugering A, Mesters RM, Parwaresch R, Domschke W, Lugering N: Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma. Eur J Haematol; 2005 May;74(5):445-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma.
  • We describe a case of primary hepatic marginal zone B-cell lymphoma in a 36-year-old Caucasian male with a history of chronic hepatitis B infection.
  • Immunohistochemically, extensive infiltration by a CD20-positive, CD5- negative and CD10-negative lymphoid cell population displaying a follicular arrangement was detected.
  • Molecular analysis of immunoglobulin heavy chain gene rearrangements confirmed the clonal expansion of lymphoma cells.
  • Fourteen months after surgical treatment, the tumour recurred in close proximity to the liver hilus, hampering further surgery.
  • Therefore, we implemented a therapy using the monoclonal anti-CD20-antibody rituximab in a dose of 375 mg/m(2), administered four times once a week.
  • Six, 10, 18, and 26 months later the recurrent lymphoma could no longer be detected as shown by abdominal ultrasonography and CT.
  • This case report demonstrates the difficulties of treating this extremely rare liver disease and shows its response to rituximab therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Liver Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Male. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813921.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. Winnicki M, Gariepy G, Sauthier PG, Funaro D: Hodgkin lymphoma presenting as a vulvar mass in a patient with crohn disease: a case report and literature review. J Low Genit Tract Dis; 2009 Apr;13(2):110-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma presenting as a vulvar mass in a patient with crohn disease: a case report and literature review.
  • OBJECTIVE: A case of Hodgkin lymphoma of the vulva and perineum is presented along with a review of the literature.
  • Incisional biopsy of the vulvar mass revealed histologic diagnosis and immunohistochemistry typical of classic Hodgkin lymphoma.
  • Imaging revealed involvement of multiple lymph nodes as well as the liver.
  • The patient was designated as having stage IV disseminated Hodgkin lymphoma, and chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine was instituted.
  • A significant reduction of the size of the vulvar mass was observed following 8 cycles of chemotherapy.
  • CONCLUSIONS.: Lymphoma of the vulva is rare with the majority being of the non-Hodgkin lymphoma type.
  • The most common subtypes of vulvar lymphoma reported are diffuse large B-cell lymphoma and follicular lymphoma.
  • Perianal Hodgkin lymphoma is also very rare but has been reported in association with human immunodeficiency virus infection, Epstein-Barr virus infection, and Crohn disease.
  • This is only the second reported case of Hodgkin lymphoma of the vulva and the second case of Hodgkin lymphoma involving the perianal area in a female patient.
  • There is currently no evidence that Crohn disease is associated with an increased risk of Hodgkin lymphoma.


21. Andersson PO, Brune M, Ekman T: Remission inversion and no transplant-related mortality--a single centre experience of autologous stem cell transplantation in malignant lymphoma. Acta Oncol; 2000;39(7):849-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission inversion and no transplant-related mortality--a single centre experience of autologous stem cell transplantation in malignant lymphoma.
  • Between 1989 and 1998 93 patients with malignant lymphoma were treated, in our centre, with high-dose chemotherapy and autologous stem cell transplantation.
  • Diagnosis according to the REAL-classification were: 38 patients with high-grade lymphoma (diffuse large B-cell lymphoma (DLCL) (n = 26), anaplastic T-cell (n = 5), lymfoblastic (n = 3) and others (n = 4)), 31 patients with low-grade lymphoma (follicular (n = 18), mantle cell (n = 4), B-CLL (n = 3) and others (n = 6)) and, finally, 24 patients with Hodgkin's disease.
  • One patient died 11 months post-transplant in unexplained liver failure and all other causes of death were related to relapse of lymphoma.
  • (b) follicular (18 patients, 3-year probability) OS 79%, PFS 52%;.
  • (c) Hodgkin's lymphoma (24 patients, 5-year probability) OS 65%, PFS 55%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma / mortality. Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11145444.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


22. Kampmann P, Højlyng N, Pedersen M: [Life-threatening liver failure and severe dyscrasias in blood and lymph nodes caused by sulphasalazine]. Ugeskr Laeger; 2006 Sep 25;168(39):3331-3
Hazardous Substances Data Bank. SULFASALAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Life-threatening liver failure and severe dyscrasias in blood and lymph nodes caused by sulphasalazine].
  • We report a case of sulphasalazine-related drug-induced hypersensitivity syndrome (the "three-week sulphasalazine syndrome") in which periferal T-cell lymphoma was a provisory diagnosis.
  • A 40-year-old woman with seropositive rheumatoid arthritis was admitted to a local hospital 26 days after initiation of sulphasalazine treatment.
  • Lymph node biopsy showed altered follicular architecture, a diffuse CD 4 positive predominance and histiocytes with erythrophagocytosis.
  • Investigation by gene rearrangement for clonality of B- and T-lymphocytes ruled out the suspicion of lymphoma.
  • Haematological and near-fatal hepatological changes resolved following discontinuation of sulphasalazine and a three-week course of glucocorticoid therapy.
  • Early awareness of this syndrome via measuring liver function tests on, e.g., days 14-35 in patients started on sulphasalazine is recommended.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Drug Hypersensitivity / etiology. Drug-Induced Liver Injury / etiology. Liver Failure / chemically induced. Sulfasalazine / adverse effects
  • [MeSH-minor] Adult. Blood Cell Count. Drug Eruptions / etiology. Female. Fever / chemically induced. Humans. Lymph Nodes / pathology. Plasma Cells / pathology. Syndrome

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032600.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 3XC8GUZ6CB / Sulfasalazine
  •  go-up   go-down


23. Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-López AJ, Witzig TE, White CA: Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm; 2003 Apr;18(2):165-78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
  • This was a 30-patient Phase II trial of reduced-dose (90)Y ibritumomab tiuxetan (Zevalin) RIT for patients with low-grade, follicular, or transformed B-cell NHL and mild thrombocytopenia.
  • One week later, patients were administered a therapeutic dose of 0.3 mCi/kg (11 MBq/kg) (90)Y ibritumomab tiuxetan.
  • Median radiation absorbed doses were 48 cGy to red marrow (range: 6.5-95 cGy), 393 cGy to liver (range: 92-1581 cGy), 522 cGy to spleen (range: 165-1711 cGy), 162 cGy to lungs (41-295 cGy), and 14 cGy to kidneys (0.03-65 cGy).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods. Thrombocytopenia / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adolescent. Antigens, CD20 / immunology. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Radiometry. Salvage Therapy. Tissue Distribution. Tomography, Emission-Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12804042.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


24. Sperotto A, Silvestri F, Fanin R, Damiani D, Geromin A, Cerno M, Stocchi R, Patriarca F, Baccarani M: Feasibility of autologous stem cell transplantation in chronic carriers of hepatitis B and hepatitis C virus. Leuk Lymphoma; 2000 Jan;36(3-4):323-30
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are several reports describing acute liver decompensation in chronic carriers of HBsAg after withdrawal of chemotherapy or immunosuppressive therapy; recently the same was also reported for chronic HCV-RNA carriers.
  • Nine patients (4 HBsAg) were affected by non-Hodgkin's lymphoma, 1 (HCV-RNA) by chronic myelogenous leukaemia and 1 (HBsAg) by breast cancer.
  • All patients are alive at 56 months (20-122) from diagnosis.
  • Currently 10/11 patients are in complete remission, while 1 patient, affected by follicular centre lymphoma, is alive with disease 52 months from autologous stem cell transplantation.
  • Our study shows that both conventional therapy and high-dose chemotherapy can be performed safely in chronic hepatitis B and C virus carriers.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Lymphoma / complications. Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Carrier State. Feasibility Studies. Female. Follow-Up Studies. Humans. Liver / drug effects. Liver / metabolism. Male. Melphalan / therapeutic use. Middle Aged. Transplantation Conditioning. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10674904.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  •  go-up   go-down


25. Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P, Metcalf D, Scott CL, Cory S: Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood; 2010 Oct 28;116(17):3197-207
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
  • Rather than the follicular lymphomas typical of vavP-BCL-2 mice, aging vavP-Mcl-1 mice were primarily susceptible to lymphomas having the phenotype of a stem/progenitor cell (11 of 30 tumors) or pre-B cell (12 of 30 tumors).
  • Furthermore, lethally irradiated mice transplanted with E13 fetal liver cells from Mcl-1/Myc bitransgenic mice uniformly died of stem/progenitor cell tumors.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4907-13 [17317859.001]
  • [Cites] Science. 1999 Nov 26;286(5445):1735-8 [10576740.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14943-8 [10611317.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):23-7 [10640272.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17961-6 [19004807.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2805-15 [19064728.001]
  • [Cites] J Biol Chem. 2009 Jul 3;284(27):18311-22 [19351886.001]
  • [Cites] J Cell Biol. 2009 Nov 2;187(3):429-42 [19948485.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1018-25 [19965632.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):899-905 [20164920.001]
  • [Cites] Blood. 2010 Sep 2;116(9):1433-42 [20525924.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3902-9 [11389033.001]
  • [Cites] Dev Cell. 2001 Nov;1(5):645-53 [11709185.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1885-93 [11877256.001]
  • [Cites] J Exp Med. 2003 Oct 6;198(7):1119-26 [14517273.001]
  • [Cites] Nature. 2003 Dec 11;426(6967):671-6 [14668867.001]
  • [Cites] J Biol Chem. 2007 Aug 17;282(33):23919-36 [17561513.001]
  • [Cites] Oncol Rep. 2008 Apr;19(4):933-7 [18357378.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):374-82 [18566403.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):521-8 [18566418.001]
  • [Cites] J Mol Biol. 2008 Jul 25;380(5):958-71 [18589438.001]
  • [Cites] J Cell Biol. 2004 Jan 5;164(1):89-96 [14709542.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2276-83 [14630790.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6164-9 [15079075.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6684-91 [15153484.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] Mol Cell Biol. 1991 Feb;11(2):1176-9 [1990273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20 [7682708.001]
  • [Cites] J Cell Biol. 1995 Mar;128(6):1173-84 [7896880.001]
  • [Cites] Leuk Res. 1996 Feb;20(2):101-7 [8628007.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):6979-90 [9003774.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2301-11 [9278319.001]
  • [Cites] EMBO J. 1997 Aug 1;16(15):4628-38 [9303307.001]
  • [Cites] Blood. 1998 Jan 15;91(2):419-30 [9427694.001]
  • [Cites] Blood. 1998 Feb 1;91(3):991-1000 [9446661.001]
  • [Cites] Blood. 1998 May 1;91(9):3379-89 [9558396.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3226-39 [9787159.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1855-63 [10477714.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):393-403 [15694340.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1101-4 [15718471.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Genes Dev. 2005 Jun 1;19(11):1294-305 [15901672.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1620-6 [17062731.001]
  • [Cites] Science. 2007 Feb 9;315(5813):856-9 [17289999.001]
  • [Cites] Cell. 2007 Mar 23;128(6):1173-86 [17382885.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6217-22 [17389404.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2670-7 [10541553.001]
  • (PMID = 20631380.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA043540; United States / NCI NIH HHS / CA / R01 CA043540-22; United States / NCI NIH HHS / CA / CA43540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Mcl1 protein, mouse; 0 / Membrane Proteins; 0 / Myc protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2995351
  •  go-up   go-down


26. Wiseman GA, Leigh BR, Dunn WL, Stabin MG, White CA: Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. Cancer Biother Radiopharm; 2003 Apr;18(2):253-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Zevalin (ibritumomab tiuxetan) radioimmunotherapy is a novel treatment for non-Hodgkin's lymphoma (NHL).
  • In a 143-patient, Phase III, randomized study, the Zevalin regimen produced a significantly higher overall response rate than rituximab for relapsed or refractory, low-grade, follicular, or transformed NHL (80% versus 56%, p = 0.02).
  • Fifteen patients from the Zevalin arm of this study were randomly selected for additional radiation dosimetry. (90)Y residence times were calculated from (111)In image analysis data.
  • MIRDOSE3.1 radiation absorbed dose estimates to normal tissues were highest for spleen, testes, and liver, with considerably lower doses reaching heart, lung, intestines, red marrow, and kidneys.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Dose-Response Relationship, Radiation. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Male. Prospective Studies. Rituximab. Salvage Therapy. Tissue Distribution. Tomography, Emission-Computed. Treatment Outcome. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12804052.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


27. Tursi A, Brandimarte G, Torello M: Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Clin Gastroenterol; 2004 Apr;38(4):360-3
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy.
  • OBJECTIVE: Mucosa-associated lymphoid tissue, which has a follicular structure closely resembling Peyer patches, is absent in the normal gastric mucosa, but it can develop in several chronic conditions.
  • Since we recently detected hepatitis C virus-RNA in gastric mucosa-associated lymphoid tissue of patients with chronic hepatitis C, we tried to treat hepatitis C virus infection to evaluate the effect of antiviral therapy on gastric mucosa-associated lymphoid tissue.
  • METHODS: Eighteen patients (12 men and 6 women; mean age: 52 years, range: 33-71 years) affected by chronic hepatitis C virus and with gastric mucosa-associated lymphoid tissue were enrolled.
  • We enrolled only patients hepatitis C virus-positive, mucosa-associated lymphoid tissue-positive, and Helicobacter pylori-negative (8 patients) or hepatitis C virus-positive patients in whom anti-H. pylori therapy did not obtain disappearance of gastric mucosa-associated lymphoid tissue (10 patients).
  • Hepatitis C virus was evaluated by hepatic biopsy with histologic evaluation and serologic examination; Gastric mucosa-associated lymphoid tissue was scored using Wotherspoon score.
  • The hepatitis C virus RNA was assayed at entry and at 3 months after stopping treatment.
  • Virologic response was defined as undetectable levels of serum hepatitis C virus RNA 3 months after stopping treatment; esophagogastroduodenoscopy was repeated at this time to evaluate the effect of anti-hepatitis C virus therapy on acquired gastric mucosa-associated lymphoid tissue.
  • Hepatitis C virus cure was obtained in 11/16 patients (68.75%), and in all of them we obtained disappearance of gastric mucosa-associated lymphoid tissue (P < 0.01).
  • Hepatitis C virus infection persisted, but with very lower levels, in 5 of 16 patients (31.25%): in 3 patients gastric mucosa-associated lymphoid tissue persisted (but in 2 it decreased from grade 3 to grade 2), while in 2 it disappeared.
  • CONCLUSIONS: We showed clearly that there is a strict correlation between hepatitis C virus infection and acquired MALT, obtaining the disappearance of this acquired immunologic acquired gastric tissue curing hepatitis C virus infection.
  • However, further studies are needed to clarify there is the same correlation between hepatitis C virus infection and gastric mucosa-associated lymphoid tissue lymphomas in hepatitis C virus-positive patients.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / drug effects. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Gastric Mucosa / drug effects. Gastric Mucosa / pathology. Gastric Mucosa / virology. Humans. Liver / drug effects. Liver / pathology. Male. Middle Aged. RNA, Viral / blood. RNA, Viral / drug effects. Recombinant Proteins. Ribavirin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2004 Apr;38(4):309-10 [15087688.001]
  • (PMID = 15087696.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


28. Yang SH, Kuo SH: Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol; 2008 Apr;87(4):325-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hepatitis B virus / physiology. Lymphoma, Follicular / drug therapy. Virus Activation
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Hepatitis B / complications. Humans. Immunologic Factors / therapeutic use. Liver Function Tests. Neoplasm Staging. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17932671.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement